Bibliographic Details
| Title: |
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide. |
| Authors: |
Goel, Utkarsh, Charalampous, Charalampos, Kapoor, Prashant, Binder, Moritz, Buadi, Francis K., Dingli, David, Dispenzieri, Angela, Fonder, Amie, Gertz, Morie A., Gonsalves, Wilson I., Hayman, Suzanne R., Hobbs, Miriam A., Hwa, Yi L., Kourelis, Taxiarchis, Lacy, Martha Q., Leung, Nelson, Lin, Yi, Warsame, Rahma M., Kyle, Robert A., Rajkumar, S. Vincent |
| Source: |
Blood Cancer Journal; 3/26/2024, Vol. 14 Issue 1, p1-6, 6p |
| Subject Terms: |
LENALIDOMIDE, MULTIPLE myeloma, PROGRESSION-free survival, REFRACTORY materials, OVERALL survival |
| Abstract: |
Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance doses. In this study, we assessed the outcomes with subsequent therapies in patients with MM refractory to standard dose vs low dose lenalidomide. We retrospectively reviewed all patients with MM at our institution who received first line therapy with lenalidomide containing regimens, and assessed progression free survival (PFS) and overall survival for these patients for second line therapy, and with lenalidomide retreatment. For second line therapy, we found no difference in the PFS between standard dose refractory and low dose refractory groups (median PFS 14 months vs 14 months, p = 0.95), while the PFS for both these groups was inferior to the not refractory group (median PFS 30 months, p < 0.001 for both pairs). Similar trends were seen among these groups on lenalidomide retreatment, and on multivariable analysis. These data suggest that refractoriness to lenalidomide is not dose dependent, and definition of lenalidomide refractoriness should not depend on the dose of lenalidomide to which the disease was considered refractory. [ABSTRACT FROM AUTHOR] |
|
Copyright of Blood Cancer Journal is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
